Product Description
The protocol described in this appendix allows for light microscopic quantitation of cell viability. Cells are suspended in PBS containing trypan blue and then examined to determine the percentage of cells that have clear cytoplasm (viable cells) versus cells that have blue cytoplasm (nonviable cells). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26529666/)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Colombia | Dominican Republic | India | Philippines | Thailand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Monash Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Cerebral Palsy|Obstetric Labor, Premature
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CORD-SAFE study | P1 |
Recruiting |
Cerebral Palsy|Obstetric Labor, Premature |
None |